After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

PMV’s $70 million series D round included multiple crossover investors, a sign the biotech will join the rush of preclinical companies lining up for an IPO this year.

Crossover investors are the most prolific backers of venture rounds for companies that have gone public on NASDAQ before entering the clinic, and two of PMV Pharmaceuticals Inc.’s investors -- RA Capital and OrbiMed Advisors -- top the list (see “Top Investors Behind Preclinical IPOs”)...